2-(5-Amino-2-n-propoxyphenyl)-5,6-diethyl-4(3H)-pyrimidone

ID: ALA4522391

PubChem CID: 136197415

Max Phase: Preclinical

Molecular Formula: C17H23N3O2

Molecular Weight: 301.39

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CCCOc1ccc(N)cc1-c1nc(CC)c(CC)c(=O)[nH]1

Standard InChI:  InChI=1S/C17H23N3O2/c1-4-9-22-15-8-7-11(18)10-13(15)16-19-14(6-3)12(5-2)17(21)20-16/h7-8,10H,4-6,9,18H2,1-3H3,(H,19,20,21)

Standard InChI Key:  VPTKMCYVAHHGRE-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 22 23  0  0  0  0  0  0  0  0999 V2000
    3.6677  -13.8757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6665  -14.6952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3746  -15.1042    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0843  -14.6948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0814  -13.8721    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3728  -13.4668    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3704  -12.6497    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.9599  -13.4673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9597  -12.6501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9585  -15.1033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2511  -14.6941    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7891  -15.1015    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7890  -15.9198    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4965  -16.3272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2046  -15.9174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2007  -15.0960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4926  -14.6923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4891  -13.8751    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.1950  -13.4635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9045  -13.8690    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6104  -13.4574    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4974  -17.1444    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  1  0
  6  1  1  0
  6  7  2  0
  1  8  1  0
  8  9  1  0
  2 10  1  0
 10 11  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 12  1  0
  4 12  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 14 22  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4522391

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 301.39

Molecular Weight (Monoisotopic): 301.1790

AlogP: 2.93

#Rotatable Bonds: 6

Polar Surface Area: 81.00

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 7.93

CX Basic pKa: 4.51

CX LogP: 2.80

CX LogD: 2.70

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.80

Np Likeness Score: -0.67

References

1. Wang Z, Jiang X, Zhang X, Tian G, Yang R, Wu J, Zou X, Liu Z, Yang X, Wu C, Shi J, Li J, Suo J, Wang Y, Zhang R, Xu Z, Gong X, He Y, Zhu W, Aisa HA, Jiang H, Xu Y, Shen J..  (2019)  Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.,  62  (10): [PMID:31021628] [10.1021/acs.jmedchem.9b00123]

Source

Source(1):

• Scientific Literature